COVID-19 Information Center

Transmission electron microscopic image of an isolate from a case of COVID-19
  • Coronavirus

COVID-19 Information Center

Novartis is responding to COVID-19 with safety of associates and patients globally our primary concern. We are also contributing to research efforts, supporting communities and ensuring stable supply and price of essential medicines. This information center provides a central hub for updates, guidance and other resources.

Latest news

Novartis announces plan to initiate clinical study of Jakavi® in severe COVID-19 patients and establish international compassionate use program

Read More

Novartis announces further steps to protect and support associates

As the coronavirus (COVID-19) situation evolves, work from home guidance is extended and we are also supporting associates as they adapt to new working dynamics and family commitments

Read More

Novartis COVID-19 Response Fund

Novartis COVID-19 Response Fund is providing urgently-needed support for healthcare workers and communities in over 50 projects around the world.

Learn More

Guidance
  • Business people working on a computer

    Job candidates

    Novartis is supporting candidates during the COVID-19 outbreak. During this time interviews will continue as planned and, where appropriate, will be switched to virtual interviews using readily available technology.

  • Grey and white world map

    COVID-19 country resources

    Novartis provides country-specific information about coronavirus disease (COVID-19) in local languages.

Research and collaborations
  • Scientist working in a lab

    COVID-19 Therapeutics Accelerator

    Novartis has joined the accelerator, coordinated by the Bill & Melinda Gates Foundation, Wellcome and Mastercard

  • Innovative Medicines Initiative (IMI) logo

    Innovative Medicines Initiative (IMI)

    Novartis is part of a consortium engaging with the Innovative Medicines Initiative (IMI) on their COVID-19 directed efforts.

  • Novartis Compound Library

    EFPIA call for therapeutic treatments R&D

    Novartis is making available several compounds from our libraries that are considered suitable for in vitro antiviral testing

  • Three researchers work in a lab

    Novartis research into Coronavirus (COVID-19)

    Novartis is also rapidly evaluating other existing products to see if any could be utilized beyond their approved indications in response to the pandemic.

Perspectives
Resources